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We investigated the effect of a novel Wnt/-catenin signaling inhibitor, AV65 on 2 
imatinib mesylate (IM)-sensitive and -resistant human chronic myeloid leukemia 3 
(CML) cells in vitro. AV65 inhibited the proliferation of various CML cell lines 4 
including T315I mutation-harboring cells. AV65 reduced the expression of -catenin in 5 
CML cells, resulting in the induction of apoptosis. Moreover, AV65 inhibited the 6 
proliferation of hypoxia-adapted primitive CML cells that overexpress -catenin. The 7 
combination of AV65 with IM had a synergistic inhibitory effect on the proliferation of 8 
CML cells. These findings suggest that AV65 could be a novel therapeutic agent for the 9 
treatment of CML.  10 
 11 
 12 




1. Introduction 1 
 Chronic myeloid leukemia (CML) is a disorder of hematopoietic stem cells 2 
caused by constitutive activation of the Bcr-Abl tyrosine kinase [1]. Imatinib mesylate 3 
(IM) has dramatically improved the management of CML [2,3], but IM resistance is 4 
frequently observed, especially in patients with advanced-stage disease [4]. The 5 
second-generation Abl tyrosine kinase inhibitors (TKIs) including dasatinib [5], 6 
nilotinib [6], bosutinib [7], and bafetinib (INNO-406)  [8], have been shown to 7 
overcome IM-resistance in CML. These agents, however, are ineffective in CML cells 8 
harboring the T315I mutation [9,10]. Another important cause of recurrence of CML is 9 
the existence of CML stem cells that are resistant to TKIs [11,12]. 10 
Granulocyte-macrophage progenitors from patients in the blast crisis phase of CML or 11 
with IM-resistant CML have elevated levels of nuclear -catenin [13]. Recently, a 12 
microarray study of cells from CML patients in blast crisis revealed an activation of the 13 
Wnt/-catenin pathway [14]. A recent gene profile study revealed the upregulation of 14 
-catenin target genes in IM-resistant CML patients in the chronic phase [15]. Moreover, 15 
loss of -catenin impairs the self-renewal of CML stem cells [16]. These observations 16 
indicate that Wnt/-catenin signaling play a role in the maintenance of CML stem cells 17 
as well as IM-resistance. Moreover, Bcr-Abl stabilizes -catenin through tyrosine 18 
5 
 
phosphorylation [17]. Therefore, the Wnt/-catenin signaling pathway could be a 1 
promising therapeutic target for the treatment of CML. 2 
Activation of Wnt/-catenin signaling is closely linked to the process of 3 
carcinogenesis in solid tumors [18] as well as leukemia [19,20]. Using high-throughput 4 
transcriptional screening (HTS) technology, effective inhibitors of Wnt/-catenin 5 
signaling were identified from a library of more than 100,000 chemical compounds 6 
[21,22]. From this initial series, a novel Wnt/-catenin signaling pathway inhibitor 7 
named AV65 was selected and optimized. In the present report, the inhibitory effect of 8 
AV65 on the proliferation of various IM-sensitive and -resistant CML cell lines is 9 
demonstrated. 10 
 11 
2. Material and methods 12 
2.1. Reagents and cell lines  13 
 The human CML cell lines K562 and, MEG01, and the HL60 acute myeloid 14 
leukemia (AML) cell line, were obtained from the American Type Culture Collection 15 
(Manassas, VA). The KU812 and BV173 CML cell lines were obtained from the 16 
Japanese Collection of Research Biosources (Osaka, Japan) and the Deutsche 17 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH (Braunschweig, 18 
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Germany), respectively. The KCL22 CML cell line was kindly provided by Dr. Tadashi 1 
Nagai (Jichi Medical School, Tochigi, Japan). The MYL and MYL-R1 CML cell lines 2 
were kindly provided by Dr. Hideo Tanaka (Hiroshima University, Japan). The MYL-R1 3 
is a Lyn-overexpressing subline of MYL [23]. The KT-1 cell line was provided by Dr. 4 
Masaki Yasukawa (Ehime University, Japan) [24].  K562-IMR cells with Bcr-Abl 5 
upregulation and K562/D1-9 cells with P-glycoprotein (P-gp)-overexpression were 6 
kindly provided by Dr. Yoshimasa Urasaki and Dr. Dr. Takahiro Yamauchi, respectively 7 
(Fukui University, Japan). The KBM5 cell line and the KBM5/STI-R subclone 8 
harboring the T315I mutation were kindly provided by Dr. Miloslav Beran (MD 9 
Anderson Cancer Center, Houston, TX) [25,26]. Ba/F3 cell lines expressing 10 
Bcr-Abl/wild-type (wt), G250E, Q252H, Y253F, E255K, T315I, T315A, F317L, F317V, 11 
M351T, or H396P were established as previously described [8]. The parental Ba/F3 cell 12 
line was maintained in 10% WEHI-conditioned medium as a source of IL-3. Two 13 
hypoxia-adapted (HA-) CML cell lines were generated, and these hypoxia-adapted 14 
sublines from K562 and KCL22 are denoted as K562/HA and KCL22/HA, respectively. 15 
Both cell lines proliferate continuously under 1.0% O2 for more than 1 year without any 16 
additional nutrient supplies. These cell lines are resistant to IM [27,28]. Cells were 17 
maintained as suspension cultures in RPMI1640 (Gibco, Tokyo, Japan) containing 10% 18 
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heat-inactivated fetal calf serum (FSC; Invitrogen, Tokyo, Japan), 2 mM L-glutamine 1 
(Gibco), and 1% penicillin-streptomycin (Gibco).  2 
AV65, a novel Wnt/-catenin inhibitor, was dissolved in dimethyl sulfoxide to 3 
a stock of 1 mM and stored in aliquots at -20C until use. The caspase inhibitor zVAD, 4 
which was purchased from the Peptide Institute (Osaka, Japan), was dissoloved in 5 
dimethyl sulfoxide and stored at -20C until required for use. zVAD was used at 50 µM 6 
for K562 and BV173, as previously described [29]. MG132, a proteasome inhibitor, was 7 
purchased from Sigma-Aldrich (Tokyo, Japan). 8 
 9 
2.2. Growth inhibitory effect of AV65 on CML cells  10 
 CML cell lines were exposed to AV65 for 72 hours and cell proliferation was 11 
assessed using a modified MTT assay as previously described [8]. The combined effect 12 
of combination treatment with IM and AV65 was evaluated in K562 cells. Cells were 13 
incubated for 72 hours with six concentrations (equivalent to 0.25, 0.5, 0.75, 1.0, 1.5, or 14 
2.0 times the IC50) of AV65 alone or in combination with IM. We calculated the 15 
combination indexes (CIs) as reported previously [30,31], and the fraction affected (Fa) 16 
at each dilution was measured (an Fa of 0.25 equals 75% viable cells). This method 17 
provides a quantification of the synergism (CI < 1) and antagonism (CI > 1) between 18 
8 
 
two drugs at different doses. Calculations of the CI were made under the assumption 1 
that the mechanisms of action of the evaluated drugs were not mutually exclusive. The 2 
inhibitory effects of AV65 on primary CML cells were also investigated using a colony 3 
assay. Bone marrow (BM) mononuclear cells obtained from CML patients and healthy 4 
volunteers (ALLCells, Emeryville, CA) were plated in duplicate in MethoCult H4434 5 
Classic (StemCell Technologies Inc, Vancouver, Canada) and cultured at 37ºC in 5% 6 
CO2. After 14 days of culture, colonies were evaluated under an inverted microscope. 7 
 8 
2.3. Western blot analysis  9 
 Following treatment with AV-65 compounds, more than 1 x 10
6
 cells were 10 
collected by centrifugation. Western blotting analysis was performed as previously 11 
described [27,32]. Antibodies (Abs) against -catenin, cyclinD1, phosphorylated Erk1/2 12 
(pT202/pY204) (BD, Tokyo, Japan), Oct-1, c-Myc, Stat5 (Santa Cruz Biotechnology, 13 
Santa Cruz, CA), phosphorylated -catenin (Ser33/37/Thr41), survivin, Erk1/2, Akt, 14 
c-Abl, phosphorylated Akt (Ser473), phosphorylated c-Abl (Tyr245), phosphorylated 15 
Stat5 (Tyr694) (Cell Signaling Technology, Danvers, MA), Actin (Sigma-Aldrich, 16 
Tokyo, Japan), and GAPDH (CHEMICON, MA, USA) were used as primary Abs. 17 
Horseradish peroxidase-coupled IgG (Amersham Biosciences, Tokyo, Japan) was used 18 
9 
 
as a secondary Ab, and immunoreactive proteins were detected by enhanced 1 
chemiluminescence (ECL) or ECL-plus kits (Amersham Biosciences). 2 
 3 
2.4. Flow cytometric analysis  4 
 Cells were fixed and stained with propidium iodide (PI). Apoptosis induced by 5 
AV65 was determined using the Annexin V-FITC Apoptosis Detection Kit I (BD 6 
Bioscience), according to the manufacturer’s instructions. Apoptosis was also evaluated 7 
using PI and TdT-mediated dUTP-biotin nick-end labeling (TUNEL) to detect 8 
fragmented DNA as previously
 
described [33]. Cells were analyzed by FACS Canto II 9 
using the Diva software (BD Bioscience).  10 
 11 
2.5. Real-time quantitative RT-PCR  12 
 Total RNA from K562, BV173, and KBM5 cells was extracted using the 13 
QIAamp RNA Blood Mini Kit (QIAGEN, Tokyo, Japan) and subjected to reverse 14 
transcription. The mRNA levels of human p21, p27, p57, and cyclin D1 were analyzed 15 
using the LightCycler System (Roche Diagnostics, Sandhoferstae, Mannheim, 16 
Germany) with FastStart DNA Master SYBER Green I (Roche Diagnostics). Amplicons 17 
were validated by their melting curve and electrophoresis. The expression levels of the 18 
10 
 
target mRNAs were normalized with that of the housekeeping gene actin. The specific 1 
primers for p21 were fwd, 5’-TGGAGACTCTCAGGGTCGAAA-3’, and rev, 2 
5’-CGGCGTTTGGAGTGGTAGAA-3’. The specific primers for p27 were fwd, 3 
5’-CCGGCTAACTCTGAGGACAC-3’, and rev, 4 
5’-AGAAGAATCGTCGGTTGCAG-3’. The specific primers for p57 were fwd, 5’- 5 
GCGGCGATCAAGAAGCTGTC-3’, and rev, 5’- CCGGTTGCTGCTACATGAAC-3’. 6 
The specific primers for -catenin were fwd, 5’-GCCGGCTATTGTAGAAGCTG-3’, 7 
and rev, 5’-GAGTCCCAAGGAGACCTTCC-3’. The specific primers for actin were 8 
fwd, 5’-CATGTACGTTGCTATCCAGGC-3’, and rev, 9 
5’-CTCCTTAATGTCACGCACGAT-3’. 10 
 11 
2.6. Measurement of caspase activity  12 
 Caspase-3 activity in the presence of AV65 with or without zVAD was 13 
evaluated using a fluorometric protease assay kit (MBL, Aichi, Japan) as previously 14 
describe [34]. 15 
 16 
3. Results 17 
3.1. AV65 inhibited the growth of IM-sensitive human CML cell lines  18 
11 
 
 Examination of -catenin expression in IM-sensitive CML cell lines showed 1 
that the expression levels of -catenin increased by 20- to 45-fold in the K562, BV173, 2 
KT-1, and MYL CML cell lines compared with the total BM cells from healthy 3 
volunteers (Fig. 1A). Assessment of the effect of AV65 showed that the inhibitor 4 
reduced -catenin expression in K562 CML cells in a time- and dose-dependent manner 5 
in nuclear and cytosolic fractions, as well as in whole cell lysates (Fig. 1B). 6 
The effect of AV65 on the growth inhibition of IM-sensitive CML cells was 7 
examined by exposing 7 IM-sensitive human CML cell lines to AV65 for 72 hours and 8 
assessing the anti-proliferative effect of this inhibitor using modified MTT assay. AV65 9 
inhibited the growth of all 7 CML cell lines with IC50 values ranging from 9.8 to 33.1 10 
nM (Fig. 1C). To investigate the inhibitory effect of AV65 on primary CML cells, the 11 
number of colony-forming units (CFUs) observed following AV65 treatment of 12 
hematopoietic progenitor cells obtained from 3 healthy individual donors. CML cells 13 
obtained from 2 patients with CML in chronic phase was examined by colony assay on 14 
day 14. When normal progenitor cells were treated with 1, 3, 10, 30, 50, 70, 100 nM of 15 
AV65, the CFUs were 93.9  5.8, 91.4  7.8, 62.1  13.4, 37.6  10.3, 12.5  9.1, 1.2  16 
2.0, and 0  0 % of the control, respectively. When primary CML cells were treated with 17 
1, 3, 10, 30, 50, 70, and 100 nM of AV65, the CFUs were 79.9  2.7, 45.8  26.1, 22.8  18 
12 
 
19.4, 26.2  1.5, 11.0  15.52, 1.626  2.3, and 0  0 % of the control, respectively (Fig. 1 
1d). These percentages are the mean  standard error of the individuals tested. These 2 
observations indicate that AV65 was approximately 5 times more effective at inhibiting 3 
colony formation in cells derived from CML patients than in those from healthy 4 
volunteers.  5 
The effect of AV65 treatment on the expression of -catenin and its downstream targets 6 
was investigated by Western blot analysis (Fig. 2A). AV65 downregulated the 7 
expression of phosphorylated and total -catenin. Moreover, the expression of c-myc 8 
and survivin were also reduced by AV65 treatment. Another work form our group 9 
demonstrated that AV65 promotes the degradation of -catenin via the 10 
ubiquitin-proteasome pathway (Yao, in revision). Therefore, we investigated the 11 
inhibitory effect of the proteasome inhibitor MG132 on the degradation of -catenin by 12 
AV65. MG132 expectedly inhibited the degradation of -catenin (Supplementary Fig. 13 
S3). 14 
 15 
3.2. AV65 caused cell arrest at the G1 phase to S phase transition and induced 16 
apoptosis in CML cells  17 
 To investigate the cell cycle phases involved in cell death induced by AV65in 18 
13 
 
CML cells, co-staining of cells by PI and TUNEL was performed to detect DNA 1 
fragmentation. Double staining revealed that both K562 and BV173 arrested at the G1 2 
to S phase transition in response to AV65 treatment at 30 nM for 12 hours (Fig. 3A). 3 
Cell cycle analysis also showed that AV65 treatment increased the G1 phase population 4 
in these 2 cell lines in a time- and dose-dependent manner, coincident with an increase 5 
in the number of cells in subG1 phase (Fig. 3B). To further identify the mechanism of 6 
cell cycle-dependent cell death, the  transcript levels of cyclin-dependent kinase 7 
inhibitors (CKIs) were assessed during the G1 phase in CML cell lines. Real time PCR 8 
analysis showed that the transcripts of p21, p27, and p57 were increased by AV65 9 
treatment in K562, BV173, and KBM5 cells. However, p53 transcript levels in these 10 
cell lines were not altered by AV65 treatment (Fig. 3C). These data indicate that AV65 11 
induced cell cycle arrest in a p53-independent manner. 12 
Assessment of apoptosis by PI/Annexin V double staining revealed that AV65 13 
induced apoptosis in K562 and BV173 cell lines in a time- and dose-dependent manner 14 
(Fig. 4A). Treatment with zVAD partially suppressed AV65-induced apoptosis in 15 
BV173 cells, which indicates that AV65 induced caspase-dependent apoptosis in BV173 16 
cells (Fig. 4B). In K562 cells, however, the effect of AV65 on the induction of apoptosis 17 
did not change with zVAD treatment (Fig. 4B), despite the inhibition of caspase-3 by 18 
14 
 
zVAD (data not shown). These results show that AV65 inhibited -catenin/T cell factor 1 
(TCF) transcription signaling, which result in cell cycle arrest in the G1 phase through 2 
the upregulation of CKIs and the induction of apoptosis in CML cells. 3 
 4 
3.3. AV65 enhanced the effect of imatinib 5 
 Bcr-Abl is reported to stabilize -catenin in CML cells through tyrosine 6 
phosphorylation [17]. The expression pattern of Bcr-Abl and its downstream effector 7 
proteins was therefore examined (Supplementary Fig. S1). Interestingly, the expression 8 
of Bcr-Abl and its phosphorylated form was downregulated by AV65, and the levels of 9 
phosphorylated Erk1/2, Akt, and Stat5 were also decreased. To investigate the combined 10 
effects of AV65 and IM on K562 cells, cell proliferation was assessed using a modified 11 
MTT assay with 6 concentrations (0.25, 0.5, 0.75, 1.0, 1.5, or 2.0 times the IC50) of each 12 
agent or a combination using a constant ratio of one of the drugs. The IC50 value for 13 
AV65, which was obtained as described above, was 10 nM, and that of IM was 100 M. 14 
The CIs and the Fa values at each dilution were calculated using the CalcuSyn software. 15 
Dose-effects and CI-Fa plots describing the effects of AV65 and IM combinations are 16 
shown in Fig. 5. As shown in Fig. 5A, combination treatment with AV65 and IM caused 17 
a greater inhibition of cell growth each agent alone. Data derived from the analysis of 18 
15 
 
CI-Fa plots are shown in Fig. 5B. The CIs at Fa 0.5 and Fa 0.8 were 1.07 and 0.88, 1 
respectively, indicating that AV65 and IM had an additive effect at lower concentrations 2 
and a synergistic effect at higher concentrations. 3 
 4 
3.4. AV65 inhibited the growth of IM-resistant CML cells  5 
 The effect of AV65 was investigated 4 IM-resistant CML cells, namely, 6 
KBM5/STI-R (harboring the T315I mutatuion), K562/IMR (containing a Bcr-Abl 7 
amplification), MYL-R1 (Lyn overexpressing), and K562/D1-9 (P-gp overexpressing). 8 
The IC50 values for AV65 in KBM5/STI-R, K562/IMR, MYL-R1, and K562/D1-9 cells 9 
were 16.0, 10.0, 47.7, and 60.1 nM, respectively, and the response of these IM-resistant 10 
cell lines were similar to those of their parental cell lines with the exception of 11 
K562/D1-9 (Fig. 6A). AV65 induced apoptosis in KBM5/STI-R and KBM5 cells (Fig. 12 
6B). Evaluation of effects of AV65 on Ba/F3 cells expressing 10 different Bcr-Abl 13 
mutations showed that AV65 inhibited the growth of Ba/F3 cells harboring various 14 
mutations, including T315I with IC50 values ranging from 21.6 to 46.5 nM 15 
(Supplementary Fig. S2).  16 
 17 
3.5. AV65 is also effective in primitive HA-CML cells  18 
16 
 
 The effect of AV65 was examined in the HA-CML cell lines, K562/HA and 1 
KCL22/HA. These cells have a phenotype that mimics characteristics of primitive 2 
leukemia cells [27,28]. In Western blotting analysis, K562/HA and KCL22/HA cells 3 
expressed higher levels of -catenin than their respective parental cells. AV65 inhibited 4 
the growth of K562/HA and KCL22/HA cells at a concentration similar to that effective 5 
in the inhibition of growth in the parental cell lines (Fig. 6C). These observations 6 
indicate that AV65 could be effective in the inhibition of the growth of primitive CML 7 
cells that overexpress -catenin. 8 
 9 
4. Discussion 10 
 Recently, activation of the Wnt/-catenin signaling pathway has been 11 
implicated in the progression of CML. The granulocyte-macrophage progenitors from 12 
patients with CML in the blast crisis phase and IM-resistant CML have elevated levels 13 
of nuclear -catenin, resulting in the transcriptional activation of TCF proteins [13]. 14 
Gene expression profile studies demonstrated that Wnt/-catenin signaling is activated 15 
in IM-resistant and advanced-stage CML [14,15], and this effect could be caused by 16 
glycogen synthase kinase 3 missplicing [35]. 17 
 -catenin is a downstream effector of the canonical Wnt signaling pathway. 18 
17 
 
The activation of the Wnt pathway is closely linked to carcinogenesis [18,36]. While the 1 
N-terminal phosphorylation of -catenin triggers its ubiquitination and degradation by 2 
the 26S proteasome [37], the stabilized form of -catenin translocates into the nucleus 3 
and activates the transcription of Wnt target genes including c-myc, survivin, and cyclin 4 
D1, resulting in the proliferation of cancer cells. -catenin therefore is considered a 5 
therapeutic target for the development of anticancer drugs[32,38-40], In prior studies, 6 
AV65 was identified as a novel inhibitor of Wnt/-catenin signaling using 7 
transcriptional profiling and HTS technology [21,22], Gene expression profiles before 8 
and after siNRA-mediated knockdown of -catenin were compared, and candidate 9 
genes that were modulated by the inhibition of the pathway were identified. A 10 
consensus set of candidate genes was identified and their transcriptional profiles were 11 
validated using a series of small molecule probes capable of inhibiting the 12 
Wnt/-catenin pathway. An early stage series of compounds was selected for further 13 
analysis as inhibitors of the Wnt/-catenin pathway. Ultimately, AV-65 was generated 14 
(Yao, in revision). 15 
In the present study, the effect of AV65 on the suppression of the proliferation 16 
of IM-sensitive and -resistant CML cells was demonstrated. AV65 decreased -catenin 17 
protein levels in CML cell lines in a time- and dose-dependent manner (Fig. 1B). Work 18 
18 
 
from our group reveled that AV65 promotes the degradation of -catenin via the 1 
ubiquitin-proteasome pathway (Yao, in revision). -catenin translocation to the nucleus 2 
decreased in response to AV65 treatment (Fig. 1B). As we have demonstrated that AV65 3 
decreased TCF transcriptional activity (Yao, in revision), the expression of its 4 
downstream proteins including c-myc and survivin were also reduced (Fig. 2A), 5 
resulting in cell growth inhibition. As expected, the proteasome inhibitor suppressed the 6 
degradation of -catenin by AV65 (Supplementary Fig. S3). Flow cytometric analysis 7 
showed that AV65 induced caspase-dependent apoptosis in BV173 cells, but apoptosis 8 
was caspase-independent in K562 cells. These results suggest that the effect of AV65 on 9 
induction of apoptosis in CML cells may or may not be accompanied by the activation 10 
of caspases and that apoptosis with caspase activation varies depending on the CML cell 11 
type, as previously observed [29]. The present results, together with other data from our 12 
group (Yao, in revision), showed that AV65 inhibited TCF transcriptional activity by 13 
promoting the degradation of -catenin, which resulted in the induction of cell death. 14 
The inhibition of TCF transcriptional activity by AV65 caused the downregulation of the 15 
expression of survivin and c-myc, which are downstream effectors of -catenin. 16 
Interestingly, AV65 also decreased the expression of the phosphoryalted forms of 17 
Bcr-Abl, Erk1/2, Akt, and Stat5 (Supplementary Fig. S1). Although this mechanism 18 
19 
 
remains still unclear, these observations suggest that Wnt/-catenin signaling might play 1 
a role in the stabilization of Bcr-Abl. Further investigations are necessary to clarify this 2 
issue. 3 
Frizzled2 and Lymphoid enhancer-binding factor-1 as well as -catenin are 4 
upregulated in CD34-positive CML cells during the disease progression from chronic 5 
phase to blastic crisis, and Wnt3a increases -catenin expression in CD34-positive CML 6 
cells [41]. These observations suggest that Wnt/-catenin signaling plays an important 7 
role in the CML progression. Therefore, the strategy targeting Wnt/-catenin signaling 8 
might be also effective for the treatment of advanced-stage CML. 9 
In the present study, the effects of AV65 were shown to be independent from 10 
Bcr-Abl expression levels, Lyn overexpression, or the Abl T315I mutation in human 11 
CML cell lines. AV65 is also effective against Ba/F3 cells expressing different mutant 12 
forms of Bcr-Abl, including T315I. These observations indicate that AV65 is effective 13 
against IM-resistant CML cells. Importantly, AV65 inhibited the growth of CML cells 14 
harboring the T315I mutation. To overcome IM-resistance in CML, a second generation 15 
of TKIs has been developed. However, the T315I mutation confers resistance to all 16 
known TKIs [9,42]. Moreover, studies have demonstrated that patients with the T315I 17 
mutation have a poor prognosis [43,44]. The development of novel agents directed 18 
20 
 
against the T315I clone is therefore important, and several multi-targeted kinase 1 
inhibitors have recently been shown to be effective against the T315I mutation [45-47]. 2 
The present data demonstrate the potential of the AV65 compound as a novel agent 3 
against CML with the T315I mutation. However, the IC50 value of AV65 in K562/D1-9 4 
cells (P-gp overexpressing) was approximately 60.1 nM, which was higher than the IC50 5 
in the parental cell line and in other IM-resistant cells. This observation suggests that 6 
AV65 is a substrate of P-gp. As IM is currently the drug of choice for the treatment of 7 
CML, the effects of combination treatment with AV65 and IM were investigated and the 8 
results showed that AV65 enhanced the inhibitory effects of IM (Fig. 5). 9 
AV65 also inhibited the growth of hypoxia-adapted CML cell lines at 10 
concentrations comparable with those shown to be effective in the respective parental 11 
cell lines. Although a definite CML stem cell niche has not been identified, leukemic 12 
stem cells are located in an osteoblastic niche [48,49], which is a hypoxic region of the 13 
BM [27], The self-renewal of normal hematopoietic stem cells favors hypoxia [50] and 14 
resistance to hypoxia is one of the defining features of leukemic stem cells [51]. HA 15 
cells survive long-term under hypoxic conditions (1% O2) and include a large number of 16 
cells in a dormant state and resistant to Abl TKIs. Furthermore, these cells exhibit a 17 
higher engraftment activity than their parental cells and possess stem cell-like 18 
21 
 
characteristics [27]. Interestingly, these HA cells showed a higher level of -catenin 1 
expression (Fig. 6C). This observation is consistent with the results reported by Dr. 2 
Jamieson [13]. Assuming that HA-CML cells exhibit characteristics similar to those of 3 
CML stem cells, the effects of AV65 on CML-HA cells were examined. AV65 inhibited 4 
the growth of HA-CML cells at similar concentrations to those inhibiting the growth of 5 
parental cells. In conclusion, AV65 inhibited the growth of CML cells harboring the 6 
T315I mutation and primitive CML cells. The present findings indicate that -catenin 7 
could be a therapeutic target in CML, and suggest that AV65 is a potential novel 8 
therapeutic agent for the treatment of CML.  9 
 10 
Conflicts of interest 11 
  R. Nagao, E. Ashihara, S. Kimura, H. Yao, M. Takeuchi, R. Tanaka, Y. 12 
Hayashi, H. Hirai, and Taira Maekawa disclose no financial conflict of interest. J.W. 13 
Strovel, Janak Padia, and Kathyrn Strand are employees of PGx Health, A Division of 14 
Clinical Data, Inc. 15 
 16 
Acknowledgements 17 
 The authors are grateful to Ms. Yoko Nakagawa for her excellent technical 18 
22 
 
support. This work was supported in part by Grant-in-Aids for Scientific Research 1 
and the Global COE Program “Center for Frontier Medicine” from the Ministry of 2 
Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by Grants 3 







[1]C.L. Sawyers, Chronic myeloid leukemia. N. Engl. J. Med. 340 (1999) 1330-1340. 3 
[2]J.M. Goldman, J.V. Melo, Chronic myeloid leukemia--advances in biology and new 4 
approaches to treatment. N. Engl. J. Med. 349 (2003) 1451-1464. 5 
[3]B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, 6 
M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, F. Cervantes, A. Hochhaus, 7 
B.L. Powell, J.L. Gabrilove, P. Rousselot, J. Reiffers, J.J. Cornelissen, T. Hughes, H. 8 
Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J.L. Nielsen, J.P. 9 
Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, R.A. Larson, 10 
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. 11 
Engl. J. Med. 355 (2006) 2408-2417. 12 
[4]A. Hochhaus, P. La Rosee, Imatinib therapy in chronic myelogenous leukemia: 13 
strategies to avoid and overcome resistance. Leukemia 18 (2004) 1321-1331. 14 
[5]H. Kantarjian, N.P. Shah, A. Hochhaus, J. Cortes, S. Shah, M. Ayala, B. Moiraghi, Z. 15 
Shen, J. Mayer, R. Pasquini, H. Nakamae, F. Huguet, C. Boque, C. Chuah, E. 16 
Bleickardt, M.B. Bradley-Garelik, C. Zhu, T. Szatrowski, D. Shapiro, M. Baccarani, 17 
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid 18 
24 
 
leukemia. N. Engl. J. Med. 362 (2010) 2260-2270. 1 
[6]G. Saglio, D.W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, C. Lobo, R. Pasquini, 2 
R.E. Clark, A. Hochhaus, T.P. Hughes, N. Gallagher, A. Hoenekopp, M. Dong, A. 3 
Haque, R.A. Larson, H.M. Kantarjian, Nilotinib versus imatinib for newly diagnosed 4 
chronic myeloid leukemia. N. Engl. J. Med. 362 (2010) 2251-2259. 5 
[7]M. Puttini, A.M. Coluccia, F. Boschelli, L. Cleris, E. Marchesi, A. Donella-Deana, S. 6 
Ahmed, S. Redaelli, R. Piazza, V. Magistroni, F. Andreoni, L. Scapozza, F. Formelli, 7 
C. Gambacorti-Passerini, In vitro and in vivo activity of SKI-606, a novel Src-Abl 8 
inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 66 (2006) 9 
11314-11322. 10 
[8]S. Kimura, H. Naito, H. Segawa, J. Kuroda, T. Yuasa, K. Sato, A. Yokota, Y. 11 
Kamitsuji, E. Kawata, E. Ashihara, Y. Nakaya, H. Naruoka, T. Wakayama, K. Nasu, 12 
T. Asaki, T. Niwa, K. Hirabayashi, T. Maekawa, NS-187, a potent and selective dual 13 
Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant 14 
leukemia. Blood 106 (2005) 3948-3954. 15 
[9]Y. Deguchi, S. Kimura, E. Ashihara, T. Niwa, K. Hodohara, Y. Fujiyama, T. 16 
Maekawa, Comparison of imatinib, dasatinib, nilotinib and INNO-406 in 17 
imatinib-resistant cell lines. Leuk. Res. 32 (2008) 980-983. 18 
25 
 
[10]R. Tanaka, S. Kimura, Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: 1 
from the second to third generation. Expert. Rev. Anticancer Ther. 8 (2008) 2 
1387-1398. 3 
[11]F. Michor, T.P. Hughes, Y. Iwasa, S. Branford, N.P. Shah, C.L. Sawyers, M.A. 4 
Nowak, Dynamics of chronic myeloid leukaemia. Nature 435 (2005) 1267-1270. 5 
[12]M. Copland, A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, N. Jordanides, M. 6 
Barow, J.C. Mountford, T.L. Holyoake, Dasatinib (BMS-354825) targets an earlier 7 
progenitor population than imatinib in primary CML but does not eliminate the 8 
quiescent fraction. Blood 107 (2006) 4532-4539. 9 
[13]C.H. Jamieson, L.E. Ailles, S.J. Dylla, M. Muijtjens, C. Jones, J.L. Zehnder, J. 10 
Gotlib, K. Li, M.G. Manz, A. Keating, C.L. Sawyers, I.L. Weissman, 11 
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis 12 
CML. N. Engl. J. Med. 351 (2004) 657-667. 13 
[14]J.P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah, 14 
W. Stock, C.L. Willman, S. Friend, P.S. Linsley, Gene expression changes associated 15 
with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U. 16 
S. A. 103 (2006) 2794-2799. 17 
[15]S.K. McWeeney, L.C. Pemberton, M.M. Loriaux, K. Vartanian, S.G. Willis, G. 18 
26 
 
Yochum, B. Wilmot, Y. Turpaz, R. Pillai, B.J. Druker, J.L. Snead, M. MacPartlin, S.G. 1 
O'Brien, J.V. Melo, T. Lange, C.A. Harrington, M.W. Deininger, A gene expression 2 
signature of CD34+ cells to predict major cytogenetic response in chronic-phase 3 
chronic myeloid leukemia patients treated with imatinib. Blood 115 (2010) 315-325. 4 
[16]C. Zhao, J. Blum, A. Chen, H.Y. Kwon, S.H. Jung, J.M. Cook, A. Lagoo, T. Reya, 5 
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. 6 
Cancer Cell 12 (2007) 528-541. 7 
[17]A.M. Coluccia, A. Vacca, M. Dunach, L. Mologni, S. Redaelli, V.H. Bustos, D. 8 
Benati, L.A. Pinna, C. Gambacorti-Passerini, Bcr-Abl stabilizes beta-catenin in 9 
chronic myeloid leukemia through its tyrosine phosphorylation. Embo. J. 26 (2007) 10 
1456-1466. 11 
[18]M. Katoh, M. Katoh, WNT signaling pathway and stem cell signaling network. Clin 12 
Cancer Res. 13 (2007) 4042-4045. 13 
[19]L. Ysebaert, G. Chicanne, C. Demur, F. De Toni, N. Prade-Houdellier, J.B. 14 
Ruidavets, V. Mansat-De Mas, F. Rigal-Huguet, G. Laurent, B. Payrastre, S. Manenti, 15 
C. Racaud-Sultan, Expression of beta-catenin by acute myeloid leukemia cells 16 




[20]Q.L. Wu, C. Zierold, E.A. Ranheim, Dysregulation of Frizzled 6 is a critical 1 
component of B-cell leukemogenesis in a mouse model of chronic lymphocytic 2 
leukemia. Blood 113 (2009) 3031-3039. 3 
[21]K.J. Strand, H. Khalak, J.W. Strovel, R. Ebner, M. Augustus, Expression biomarkers 4 
for clinical efficacy and outcome prediction in cancer. Pharmacogenomics 7 (2006) 5 
105-115. 6 
[22]D. Bol, R. Ebner, Gene expression profiling in the discovery, optimization and 7 
development of novel drugs: one universal screening platform. Pharmacogenomics 7 8 
(2006) 227-235. 9 
[23]T. Ito, H. Tanaka, A. Kimura, Establishment and characterization of a novel 10 
imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant 11 
subline MYL-R showing overexpression of Lyn. Eur. J. Haematol. 78 (2007) 12 
417-431. 13 
[24]K. Yanagisawa, H. Yamauchi, M. Kaneko, H. Kohno, H. Hasegawa, S. Fujita, 14 
Suppression of cell proliferation and the expression of a bcr-abl fusion gene and 15 
apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, 16 
by interferon-alpha. Blood 91 (1998) 641-648. 17 
[25]M. Beran, P. Pisa, S. O'Brien, R. Kurzrock, M. Siciliano, A. Cork, B.S. Andersson, 18 
28 
 
V. Kohli, H. Kantarjian, Biological properties and growth in SCID mice of a new 1 
myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous 2 
leukemia cells in the blastic phase. Cancer Res. 53 (1993) 3603-3610. 3 
[26]H. Zhang, D. Trachootham, W. Lu, J. Carew, F.J. Giles, M.J. Keating, R.B. 4 
Arlinghaus, P. Huang, Effective killing of Gleevec-resistant CML cells with T315I 5 
mutation by a natural compound PEITC through redox-mediated mechanism. 6 
Leukemia 22 (2008) 1191-1199. 7 
[27]M. Takeuchi, S. Kimura, J. Kuroda, E. Ashihara, M. Kawatani, H. Osada, K. 8 
Umezawa, E. Yasui, M. Imoto, T. Tsuruo, A. Yokota, R. Tanaka, R. Nagao, T. 9 
Nakahata, Y. Fujiyama, T. Maekawa, Glyoxalase-I is a novel target against Bcr-Abl+ 10 
leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell 11 
Death. Differ. 17 (2010) 1211-1220. 12 
[28]M. Takeuchi, E. Ashihara, Y. Yamazaki, S. Kimura, Y. Nakagawa, R. Tanaka, H. 13 
Yao, R. Nagao, Y. Hayashi, H. Hirai, T. Maekawa, Rakicidin A effectively induces 14 
apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. Cancer Sci. 102 15 
(2011) 591-596. 16 
[29]Y. Kamitsuji, J. Kuroda, S. Kimura, S. Toyokuni, K. Watanabe, E. Ashihara, H. 17 
Tanaka, Y. Yui, M. Watanabe, H. Matsubara, Y. Mizushima, Y. Hiraumi, E. Kawata, T. 18 
29 
 
Yoshikawa, T. Maekawa, T. Nakahata, S. Adachi, The Bcr-Abl kinase inhibitor 1 
INNO-406 induces autophagy and different modes of cell death execution in 2 
Bcr-Abl-positive leukemias. Cell Death. Differ. 15 (2008) 1712-1722. 3 
[30]E. Kawata, E. Ashihara, Y. Nakagawa, T. Kiuchi, M. Ogura, H. Yao, K. Sakai, R. 4 
Tanaka, R. Nagao, A. Yokota, M. Takeuchi, S. Kimura, H. Hirai, T. Maekawa, A 5 
combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid 6 
suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett. 294 7 
(2010) 245-253. 8 
[31]S. Kimura, J. Kuroda, H. Segawa, K. Sato, M. Nogawa, T. Yuasa, O.G. Ottmann, T. 9 
Maekawa, Antiproliferative efficacy of the third-generation bisphosphonate, 10 
zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int. J. 11 
Hematol. 79 (2004) 37-43. 12 
[32]E. Ashihara, E. Kawata, Y. Nakagawa, C. Shimazaski, J. Kuroda, K. Taniguchi, H. 13 
Uchiyama, R. Tanaka, A. Yokota, M. Takeuchi, Y. Kamitsuji, T. Inaba, M. Taniwaki, 14 
S. Kimura, T. Maekawa, beta-catenin small interfering RNA successfully suppressed 15 
progression of multiple myeloma in a mouse model. Clin. Cancer Res. 15 (2009) 16 
2731-2738. 17 
[33]S. Kimura, T. Maekawa, K. Hirakawa, A. Murakami, T. Abe, Alterations of c-myc 18 
30 
 
expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in 1 
HL-60 cells. Cancer Res. 55 (1995) 1379-1384. 2 
[34]I. Kubonishi, I. Miyoshi, Establishment of a Ph1 chromosome-positive cell line 3 
from chronic myelogenous leukemia in blast crisis. Int. J. Cell Cloning 1 (1983) 4 
105-117. 5 
[35]A.E. Abrahamsson, I. Geron, J. Gotlib, K.H. Dao, C.F. Barroga, I.G. Newton, F.J. 6 
Giles, J. Durocher, R.S. Creusot, M. Karimi, C. Jones, J.L. Zehnder, A. Keating, R.S. 7 
Negrin, I.L. Weissman, C.H. Jamieson, Glycogen synthase kinase 3beta missplicing 8 
contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U. S. A. 106 9 
(2009) 3925-3929. 10 
[36]P. Polakis, The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17 (2007) 11 
45-51. 12 
[37]H. Aberle, A. Bauer, J. Stappert, A. Kispert, R. Kemler, beta-catenin is a target for 13 
the ubiquitin-proteasome pathway. Embo. J. 16 (1997) 3797-3804. 14 
[38]S. Dihlmann, M. von Knebel Doeberitz, Wnt/beta-catenin-pathway as a molecular 15 
target for future anti-cancer therapeutics. Int. J. Cancer 113 (2005) 515-524. 16 
[39]M. Lepourcelet, Y.N. Chen, D.S. France, H. Wang, P. Crews, F. Petersen, C. Bruseo, 17 
A.W. Wood, R.A. Shivdasani, Small-molecule antagonists of the oncogenic 18 
31 
 
Tcf/beta-catenin protein complex. Cancer Cell 5 (2004) 91-102. 1 
[40]H. Yao, E. Ashihara, T. Maekawa, Targeting the Wnt/beta-catenin signaling pathway 2 
in human cancers. Expert Opin. Ther. Targets 15 (2011) 87-. 3 
[41]A. Sengupta, D. Banerjee, S. Chandra, S.K. Banerji, R. Ghosh, R. Roy, S. Banerjee, 4 
Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling 5 
in chronic myeloid leukemia progression. Leukemia 21 (2007) 949-955. 6 
[42]H.A. Bradeen, C.A. Eide, T. O'Hare, K.J. Johnson, S.G. Willis, F.Y. Lee, B.J. Druker, 7 
M.W. Deininger, Comparison of imatinib mesylate, dasatinib (BMS-354825), and 8 
nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: 9 
high efficacy of drug combinations. Blood 108 (2006) 2332-2338. 10 
[43]S. Soverini, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, A. Poerio, I. Iacobucci, 11 
M. Amabile, E. Abruzzese, E. Orlandi, F. Radaelli, F. Ciccone, M. Tiribelli, R. di 12 
Lorenzo, C. Caracciolo, B. Izzo, F. Pane, G. Saglio, M. Baccarani, G. Martinelli, 13 
Contribution of ABL kinase domain mutations to imatinib resistance in different 14 
subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic 15 
Myeloid Leukemia. Clin. Cancer Res. 12 (2006) 7374-7379. 16 
[44]F.E. Nicolini, S. Hayette, S. Corm, E. Bachy, D. Bories, M. Tulliez, F. Guilhot, L. 17 
Legros, F. Maloisel, J.J. Kiladjian, F.X. Mahon, Q.H. Le, M. Michallet, C. 18 
32 
 
Roche-Lestienne, C. Preudhomme, Clinical outcome of 27 imatinib 1 
mesylate-resistant chronic myelogenous leukemia patients harboring a T315I 2 
BCR-ABL mutation. Haematologica 92 (2007) 1238-1241. 3 
[45]R. Tanaka, M.S. Squires, S. Kimura, A. Yokota, R. Nagao, T. Yamauchi, M. 4 
Takeuchi, H. Yao, M. Reule, T. Smyth, J.F. Lyons, N.T. Thompson, E. Ashihara, O.G. 5 
Ottmann, T. Maekawa, Activity of the multi-targeted kinase inhibitor, AT9283, in 6 
imatinib-resistant BCR-ABL positive leukemic cells. Blood 116 (2010) 2089-2095. 7 
[46]Y. Shiotsu, H. Kiyoi, Y. Ishikawa, R. Tanizaki, M. Shimizu, H. Umehara, K. Ishii, Y. 8 
Mori, K. Ozeki, Y. Minami, A. Abe, H. Maeda, T. Akiyama, Y. Kanda, Y. Sato, S. 9 
Akinaga, T. Naoe, KW-2449, a novel multikinase inhibitor, suppresses the growth of 10 
leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. 11 
Blood 114 (2009) 1607-1617. 12 
[47]D. Akahane, T. Tauchi, S. Okabe, K. Nunoda, K. Ohyashiki, Activity of a novel 13 
Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in 14 
vivo studies. Cancer Sci. 99 (2008) 1251-1257. 15 
[48]M. Ninomiya, A. Abe, A. Katsumi, J. Xu, M. Ito, F. Arai, T. Suda, M. Ito, H. Kiyoi, 16 
T. Kinoshita, T. Naoe, Homing, proliferation and survival sites of human leukemia 17 
cells in vivo in immunodeficient mice. Leukemia 21 (2007) 136-142. 18 
33 
 
[49]F. Ishikawa, S. Yoshida, Y. Saito, A. Hijikata, H. Kitamura, S. Tanaka, R. Nakamura, 1 
T. Tanaka, H. Tomiyama, N. Saito, M. Fukata, T. Miyamoto, B. Lyons, K. Ohshima, 2 
N. Uchida, S. Taniguchi, O. Ohara, K. Akashi, M. Harada, L.D. Shultz, 3 
Chemotherapy-resistant human AML stem cells home to and engraft within the 4 
bone-marrow endosteal region. Nat. Biotechnol. 25 (2007) 1315-1321. 5 
[50]V. Desplat, J.L. Faucher, F.X. Mahon, P. Dello Sbarba, V. Praloran, Z. Ivanovic, 6 
Hypoxia modifies proliferation and differentiation of CD34(+) CML cells. Stem 7 
Cells 20 (2002) 347-354. 8 
[51]S. Giuntoli, E. Rovida, V. Barbetti, M.G. Cipolleschi, M. Olivotto, P. Dello Sbarba, 9 
Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within 10 






Figure legends. 1 
Fig. 1. Growth inhibitory effect of AV65 in human CML cells. (A) Expression of 2 
-catenin in the K562, BV173, KT-1, and MYL CML cell lines and total BM cells from 3 
a healthy volunteer (ctrl) as a control. (B) K562 cells were treated with AV65 and the 4 
expression of -catenin was detected by Western blotting. Results represent the means 5 
of 3 independent experiments. (C) Seven imatinib-sensitive human CML cell lines were 6 
exposed to AV65 for 72 hours and anti-proliferative effects were examined using a 7 
modified MTT assay. (D) The colony-forming assay was performed in duplicate in 8 
primary CML cells obtained from patients with CML in the chronic phase and bone 9 
marrow mononuclear cells obtained from healthy volunteers was performed in duplicate. 10 
After 14 days of culture, colonies were evaluated under an inverted microscope. Data 11 
represents the mean  SD of 3 independent experiments. 12 
 13 
 14 
Fig. 2. Effect of AV65 on the expression of -catenin and its downstream targets. K562 15 
CML cells were treated with AV65 at the indicated concentrations for 72 hours. 16 





Fig 3. Cell cycle analysis and transcript levels of CDK inhibitors in AV65-treated CML 2 
cells. (A) K562 and BV173 were exposed to AV65 at a concentration of 10 nM for 12 3 
hours. Apoptosis induced by AV65 was analyzed by PI and TUNEL double staining. 4 
Each dot line in the scattergram indicates G1 phase. (B) CML cells treated with AV65 5 
were fixed and stained with PI and analyzed for DNA content by FACS Canto II. The 6 
numbers inside each histogram indicate the percentage of the subG1 fraction. The 7 
results shown in Figure 2a and b are representative of 3 independent experiments. (C) 8 
Transcript levels of CKIs in CML cells detected by real time PCR analysis. The results 9 
represent the means + SD of 3 independent experiments.  10 
 11 
Fig. 4. Induction of apoptosis by AV65 treatment in CML cells. (A) K562 and BV173 12 
cells were exposed to AV65 for 24, 48, and 72 hours at concentrations of 10 nM and 30 13 
nM. Cell were stained with PI and Annexin V-FITC and subjected to flow cytometric 14 
analysis for the determination of apoptosis. The numbers inside each histogram indicate 15 
the percentage of early apoptotic cells (Annexin-V+/PI-) and late apoptotic/necrotic 16 
cells (Annexin-V+/PI+). (B) K562 and BV173 were treated with AV65 in the presence 17 
of zVAD. Cell were stained with PI and Annexin V-FITC. The numbers inside each 18 
36 
 
histogram indicate the percentage of early apoptotic cells (Region A) and late 1 
apoptotic/necrotic cells (Region B). Results are representative of 3 independent 2 
experiments. 3 
 4 
Fig. 5. The inhibitory effects of AV65 in combination with IM on K562 cells. (A) K562 5 
cells were incubated for 72 hours with 6 concentrations (0.25, 0.5, 0.75, 1.0, 1.5, or 2.0 6 
times the IC50) of AV65 and IM or a combination of the 2 agents using the constant ratio 7 
design of a modified MTT assay. The IC50 values of AV65 and IM were 10 nM and 100 8 
M, respectively. The killing curves of the concurrent administration of AV65 and IM 9 
are shown. (B) Plots of combination index (CI) against fraction affected (Fa). CIs were 10 
determined with the nonlinear regression program CalcuSyn. 11 
 12 
Fig. 6. Inhibitory effect of AV65 on IM-resistant CML cells. (a) Four IM-resistant CML 13 
cell lines; K562/IMR (Bcr-Abl amplification), MYL-R1 (Lyn overexpressing), 14 
KBM5/STI-R (harboring the T315I mutation), and K562/D1-9 (P-gp overexpressing), 15 
were exposed to AV65 for 72 hours and its anti-proliferative effects were examined by a 16 
modified MTT assay. The results represent the means  SD of 3 independent 17 
experiments. (B) KBM5 and KBM5/ STI-R cells were exposed to AV65 for 24, 48, and 18 
37 
 
72 hours at concentration of 1 x IC50 (20 nM, 15 nM, respectively) and 3 x IC50 (60 nM, 1 
45 nM, respectively). Cell were stained with PI and Annexin V-FITC and subjected to 2 
flow cytometric analysis of apoptosis. The numbers inside each histogram indicate the 3 
percentage of early apoptotic cells (Annexin-V+/PI-) and late apoptotic/necrotic cells 4 
(Annexin-V+/PI+). Results are representative of 3 independent experiments. (C) Total 5 
protein lysates were extracted from the hypoxia-adapted CML cell lines, K562/HA and 6 
KCL22/HA. Western blotting was performed using antibodies against -catenin and 7 
Actin (upper panel). Anti-proliferative effects were examined by the modified MTT 8 
assay. Results represent the means  SD of 3 independent experiments (lower panel). 9 
10 
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